Use and Complications of High-dose Disodium Etidronate Therapy in Fibrodysplasia Ossificans Progressiva

Overview

Journal J Pediatr

Specialty Pediatrics

Date 1977 Dec 1

PMID 411907

Citations 8

Authors

J G Rogers

J P DORST

W B Geho

Affiliations

Soon will be listed here.

Abstract

A boy with fibrodysplasia ossificans progressiva received nearly twice the usual therapeutic dose of disodium etidronate for 13 months in an attempt to prevent reossification following a second operation to correct severe torticollis. The operation was successful, but during therapy he developed weakness and distinctive bone lesions characterized by general osteopenia, widened physes, and unique radiolucent bands in the metaphyses. The osseous abnormalities were distinct from those of rickets and healed after withdrawal of the drug.

Citing Articles

MYOSITIS OSSIFICANS PROGRESSIVA: CASE REPORT.

Moraes F, de Queiroz Filho A, Silva L, da Rocha V, Araujo N, Mendonca E Rev Bras Ortop. 2016; 47(3):394-6.

PMID: 27042654 PMC: 4799426. DOI: 10.1016/S2255-4971(15)30119-1.

Clinically applicable antianginal agents suppress osteoblastic transformation of myogenic cells and heterotopic ossifications in mice.

Yamamoto R, Matsushita M, Kitoh H, Masuda A, Ito M, Katagiri T J Bone Miner Metab. 2012; 31(1):26-33.

PMID: 23011467 DOI: 10.1007/s00774-012-0380-2.

Pamidronate treatment of pediatric fracture patients on chronic steroid therapy.

Acott P, Wong J, Lang B, Crocker J Pediatr Nephrol. 2005; 20(3):368-73.

PMID: 15690187 DOI: 10.1007/s00467-004-1790-8.

The role of bisphosphonates in diseases of childhood.

Srivastava T, Alon U Eur J Pediatr. 2003; 162(11):735-51.

PMID: 14523647 DOI: 10.1007/s00431-003-1298-4.

Intravenous pamidronate in juvenile osteoporosis.

Shaw N, Boivin C, Crabtree N Arch Dis Child. 2000; 83(2):143-5.

PMID: 10906023 PMC: 1718443. DOI: 10.1136/adc.83.2.143.